Last edition
News about " GlaxoSmithKline (GSK) "
GSK and LTZ Collaborate to Advance Novel Myeloid Cell Engagers in Oncology
Leveraging LTZ’s novel immune-engager platform and GSK’s oncology expertise, the partnership aims to deliver potent, safer cancer therapies that can be administered in community settings, supporting GSK’s strategy to advance transformative medicines through cutting-edge technologies.
GlaxoSmithKline (GSK) | 20/11/2025 | By Dineshwori
USFDA Approves Alembic Pharmaceuticals' Sumatriptan Single-Dose Autoinjector
Alembic Pharmaceuticals has received USFDA approval for its Abbreviated New Drug Application (ANDA) for Sumatriptan single-dose autoinjector, deemed therapeutically equivalent to GlaxoSmithKline’s Imitrex STATdose System in 4 mg/0.5 mL and 6 mg/0.5 mL strengths.
GlaxoSmithKline (GSK) | 10/11/2025 | By Dineshwori
GSK Q2 Sales Hit GBP 8 Billion, Driven Mainly by Specialty Medicines
GSK has delivered robust second-quarter 2025 results, fueled primarily by strong growth in its Specialty Medicines portfolio.
GlaxoSmithKline (GSK) | 31/07/2025 | By Dineshwori | 234
FDA to Review GSK's Application to Expand Arexvy RSV Vaccine Use
The US Food and Drug Administration (FDA) has accepted to review GlaxoSmithKline (GSK)'s application to expand the use of its RSV vaccine, Arexvy, to include adults aged 18–49 who are at increased risk.
GlaxoSmithKline (GSK) | 16/07/2025 | By Dineshwori | 193
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy